{"id":14002,"date":"2020-10-14T10:55:48","date_gmt":"2020-10-14T08:55:48","guid":{"rendered":"https:\/\/www.neurosciences.asso.fr\/2020\/10\/maladie-de-huntington-des-anomalies-cerebrales-detectables-des-le-stade-embryonnaire-chez-lhomme\/"},"modified":"2020-12-01T22:32:16","modified_gmt":"2020-12-01T20:32:16","slug":"maladie-de-huntington-des-anomalies-cerebrales-detectables-des-le-stade-embryonnaire-chez-lhomme","status":"publish","type":"post","link":"https:\/\/www.neurosciences.asso.fr\/en\/2020\/10\/maladie-de-huntington-des-anomalies-cerebrales-detectables-des-le-stade-embryonnaire-chez-lhomme\/","title":{"rendered":"Maladie de Huntington: des anomalies c\u00e9r\u00e9brales d\u00e9tectables d\u00e8s le stade embryonnaire chez l\u2019homme"},"content":{"rendered":"<p>La maladie de Huntington &#8211; comme la maladie d&#8217;Alzheimer, de Parkinson et la scl\u00e9rose lat\u00e9rale amyotrophique- fait partie de la famille des maladies qui se manifestent \u00e0 l\u2019\u00e2ge adulte alors que -en ce qui concerne les formes h\u00e9r\u00e9ditaires- l\u2019anomalie g\u00e9n\u00e9tique est pr\u00e9sente d\u00e8s la conception. Par exemple, la prot\u00e9ine huntingtine (HTT) dont la mutation du g\u00e8ne par expansion de triplets CAG conduit \u00e0 la maladie, est exprim\u00e9e tr\u00e8s pr\u00e9cocement dans le d\u00e9veloppement pendant lequel elle joue un r\u00f4le essentiel. La HTT mutante interf\u00e8re avec plusieurs \u00e9tapes du d\u00e9veloppement de certaines r\u00e9gions c\u00e9r\u00e9brales, dont le cortex. De plus, l&#8217;expression de la HTT mutante restreinte au d\u00e9veloppement suffit \u00e0 produire des caract\u00e9ristiques de la maladie de Huntington chez des souris adultes sugg\u00e9rant qu&#8217;il y a une composante d\u00e9veloppementale \u00e0 la maladie.<\/p>\n<p>Savoir si le d\u00e9veloppement c\u00e9r\u00e9bral humain pr\u00e9coce est modifi\u00e9 restait une question centrale dans le domaine. Pour y r\u00e9pondre, les \u00e9quipes de Sandrine Humbert, directrice de recherche Inserm au Grenoble Institut des neurosciences (Inserm\/Universit\u00e9 Grenoble Alpes), et Alexandra Durr, professeur des universit\u00e9s-praticien hospitalier \u00e0 Sorbonne Universit\u00e9, \u00e0 l\u2019H\u00f4pital de la Piti\u00e9 Salp\u00eatri\u00e8re &#8211; AP-HP et \u00e0 l\u2019Institut du cerveau (Inserm\/Sorbonne Universit\u00e9\/CNRS\/AP-HP) ont examin\u00e9 des tissus de f\u0153tus humains porteurs de l\u2019expansion pathologique de triplet CAG dans le g\u00e8ne HTT, issus de dons des parents suite \u00e0 une interruption m\u00e9dicale de grossesse. Ces tissus pr\u00e9sentent des anomalies dans le cortex en d\u00e9veloppement, notamment une mauvaise localisation de la huntingtine mutante et de prot\u00e9ines de complexes de jonction, des d\u00e9fauts de polarit\u00e9 et de diff\u00e9renciation des pr\u00e9curseurs neuronaux, une ciliog\u00e9n\u00e8se anormale et des changements dans la mitose et la progression du cycle cellulaire. Ces anomalies perturbent l\u2019\u00e9quilibre \u00ab division-diff\u00e9rentiation \u00bb des cellules prog\u00e9nitrices. Celles-ci sont en effet issues d\u2019un r\u00e9servoir de cellules en division dont une partie se diff\u00e9rencie en neurones tandis que l\u2019autre continue de se diviser pour fournir de nouvelles cellules prog\u00e9nitrices. Chez les embryons porteurs de la mutation, ces cellules prog\u00e9nitrices entrent plus vite en diff\u00e9renciation au d\u00e9pend du r\u00e9servoir de cellules en division.<\/p>\n<p>Ces travaux fournissent donc la premi\u00e8re preuve directe provenant de f\u0153tus humains que le d\u00e9veloppement du cerveau est alt\u00e9r\u00e9 dans une maladie neurod\u00e9g\u00e9n\u00e9rative se manifestant \u00e0 l&#8217;\u00e2ge adulte. Cette d\u00e9couverte ouvre un champ de nouvelles investigations visant \u00e0 comprendre comment ces d\u00e9fauts pr\u00e9coces contribuent \u00e0 la pathologie adulte et comment la compensation de ces derniers est r\u00e9gul\u00e9e. Cette d\u00e9couverte a aussi des cons\u00e9quences importantes pour la fa\u00e7on et le stade auxquels les traitements qui modifient le cours de la maladie doivent \u00eatre envisag\u00e9s.<\/p>\n<p><strong>Reference<\/strong><\/p>\n<p>Huntington disease alters human neurodevelopment. M Barnat, M Capizzi, E Aparicio, S Boluda, D Wennagel, R Kacher, R Kassem, S Lenoir, F Agasse, BY Braz, JP Liu, J Ighil, A Tessier, SO Zeitlin, C Duyckaerts, M Dommergues, A Durr, S Humbert. Science, 2020, 10.1126\/science.aax3338<\/p>\n<p><strong>Contact chercheuses<\/strong><\/p>\n<p><a href=\"mailto:sandrine.humbert@inserm.fr\">Sandrine Humbert<\/a><\/p>\n<p>Univ.Grenoble Alpes, INSERM,U1216, Grenoble Institut Neurosciences, Grenoble, France<\/p>\n<p><a href=\"mailto:alexandra.durr@upmc.fr\">Alexandra Durr<\/a><\/p>\n<p>Institut du Cerveau et de la MoelleEpini\u00e8re (ICM), Genetics, AP HP, Sorbonne University, InsermU1127, CNRSUMR7225, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France.<\/p>\n<p>&nbsp;<\/p>\n<p><em><strong>Huntington disease alters human neurodevelopment<\/strong><\/em><\/p>\n<p><em>Huntington disease &#8211; like amyotrophic lateral sclerosis and Alzheimer&#8217;s and Parkinson&#8217;s disease \u2013 is part of the family of diseases that shared a delayed onset in mid-adulthood despite the expression, at least in hereditary cases, of the disease-driving protein from the first days of life. For example, huntingtin, the protein mutated in Huntington disease, is expressed very early in development during which it plays a key role. In mice, mutant huntingtin interferes with several stages of development in certain brain regions, including the cortex. Furthermore, expression of mutant huntingtin restricted to development is sufficient to produce features of Huntington&#8217;s disease in adult mice suggesting that there is a developmental component to the disease.<\/em><\/p>\n<p><em>Nevertheless, whether early human brain development is altered remained a central question in the field. To answer it, teams led Sandrine Humbert, research director, INSERM (the French National Institute for Health and Medical Research) and group leader at the Grenoble Institut des Neurosciences, and by Alexandra Durr, professor at Sorbonne University and team leader in the Paris Brain Institute at Pitie-Salp\u00eatri\u00e8re Hospital, Paris had access to fetal tissue from families that terminated their pregnancy in the context of a prenatal test. The developing fetus carried the Huntington disease gene mutation. These tissues showed abnormalities in the developing cortex, including abnormal localization of mutant huntingtin and junction complex proteins, defects in polarity and differentiation of neural precursors, abnormal ciliogenesis, and changes in mitosis and cell cycle progression. These abnormalities disrupt the &#8220;division-differentiation&#8221; balance of progenitor cells. Progenitor cells come from a pool of dividing cells, some of which differentiate into neurons while the other continues to divide to provide new progenitor cells. In Huntington disease gene carrier embryos, these progenitor cells differentiate more rapidly at the expense of the pool of dividing cells.<\/em><\/p>\n<p><em>This work provides the first direct evidence from human fetuses that brain development is impaired in a neurodegenerative disease with delayed onset. This discovery opens up a field of new investigations aimed at understanding how these early defects contribute to adult pathology and how their compensation is regulated. This discovery also has important implications for the way and stage at which disease-modifying treatments should be considered.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La maladie de Huntington &#8211; comme la maladie d&#8217;Alzheimer, de Parkinson et la scl\u00e9rose lat\u00e9rale amyotrophique- fait partie de la famille des maladies qui se manifestent \u00e0 l\u2019\u00e2ge adulte alors que -en ce qui concerne les formes h\u00e9r\u00e9ditaires- l\u2019anomalie g\u00e9n\u00e9tique est pr\u00e9sente d\u00e8s la conception. Par exemple, la prot\u00e9ine huntingtine (HTT) dont la mutation du [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":14138,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[31],"class_list":["post-14002","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-actualite-en"],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 10:29:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/posts\/14002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/comments?post=14002"}],"version-history":[{"count":1,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/posts\/14002\/revisions"}],"predecessor-version":[{"id":14005,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/posts\/14002\/revisions\/14005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/media\/14138"}],"wp:attachment":[{"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/media?parent=14002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/categories?post=14002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.neurosciences.asso.fr\/en\/wp-json\/wp\/v2\/tags?post=14002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}